Business Wire

AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting

Share

AOP Health announced the final results on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from its CONTINUATION-PV study in an oral presentation at the prestigious EHA (European Hematology Association) 2022 Annual Meeting by Professor Heinz Gisslinger, Medical University of Vienna, Austria 1.

Link to abstract

Ropeginterferon alfa-2b is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to monthly after stabilization of hematological parameters.

AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA,PROUD-PV and CONTINUATION-PV. The latter is an open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of Ropeginterferon alfa-2b versus hydroxyurea (HU) or best available treatment (BAT) in patients with PV who previously participated in the PROUD-PV study.

The clinical development program conducted by AOP Health in Europe since 2010, led to marketing authorizations of BESREMi® for the treatment of PV, first granted by the European Commission in 2019, thereafter by Switzerland, Liechtenstein, Israel, Taiwan, Korea and most recently by the US FDA in November 2021.

The presentation during the EHA 2022 Annual Meeting focused on patient-relevant outcomes after this long-term (up to 7.5 years) treatment:

Symptoms/Quality of Life: only a minority of patients (15.7%) treated with Ropeginterferon alfa-2b experienced disease related symptoms, and less than 2 out of 10 patients had to undergo phlebotomy to maintain hematocrit levels during their last year of treatment.

Disease modification: Besides that, treatment with Ropeginterferon alfa-2b led to reduction of the disease-causing mutated JAK2 allele burden below 1% in a sizeable proportion of patients (>20%). Most importantly, event-free survival, with events defined as death, thrombosis, or disease progression over the entire 7.5 years treatment period, was significantly better in the Ropeginterferon alfa-2b group with only 5 of 95 patients experiencing an event, whereas in the control group such an event was observed in 12 of 74 patients (p=0.04).

“The results of CONTI-PV after 7.5 years of treatment provide further evidence of the value of BESREMi® for patients suffering from PV. We are very proud that our work not only delivered the first interferon with regulatory approval for any of the Myeloproliferative Neoplasms, but also contributed to a change of treatment paradigm in PV”, says Dr. Christoph Klade, Chief Scientific Officer of AOP Health.

Professor Jean-Jacques Kiladjian from Paris, senior author of the paper adds: “Since its first approval in Europe in 2019, Ropeginterferon alfa-2b has become the first line therapy of choice for many PV patients. The striking JAK2 molecular response and the extremely low rate of disease progression and thrombosis suggest that Ropeginterferon alfa-2b might be the best available treatment option for disease modification, which may translate into improved survival and even the chance to stop treatment for some patients.”

1Ropeginterferon alpha-2b achieves patient-specific treatment goals in Polycythaemia Vera: final results from the PROUD-PV/CONTINUATION-PV studies. Heinz Gisslinger,Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, and Jean-Jacques Kiladjian for the PROUD-PV Study Group, European Hematology Association EHA, 27th Annual Meeting June 2022

About BESREMi®

BESREMi® is a long-acting, mono-pegylated proline interferon (ATC L03AB15). Its unique pharmacokinetic properties offer a new level of tolerability. BESREMi® is designed to be conveniently self-administered subcutaneously with a pen once every two weeks, or up to monthly after stabilization of hematological parameters. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons.

For the EMA Summary of Product Characteristics please visit:BESREMi®

Ropeginterferon alfa-2b was discovered by PharmaEssentia, a long-term partner of AOP Health. In 2009, AOP Health in-licensed the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in PV and other MPNs such as chronic myelogenous leukemia (CML) for European, Commonwealth of Independent States (CIS), and Middle Eastern markets.

About Polycythaemia Vera

Polycythaemia Vera (PV) is a rare cancer of the blood-building stem cells in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. This condition increases the risk for circulatory disorders such as thrombosis and embolism, its symptoms lead to a reduced quality of life and on the long run may progress to myelofibrosis or transform to leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to blood-building stem cells in the bone marrow with a set of acquired mutations, the most important being a mutant form of JAK2 that make up the malignant clone.

Important PV treatment goals are to achieve healthy blood counts (hematocrit below 45%), improve quality of life and to slow or delay the progression of disease.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mag. Nina Roth, MAS
+43 676 3131509
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.
AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Travelex Bank Selects ThetaRay for Transaction Monitoring and Sanctions Screening6.7.2022 14:00:00 CEST | Press release

ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced that Travelex Bank, Brazil’s largest foreign exchange specialist, will implement ThetaRay’s SONAR anti-money laundering (AML) SaaS solution for both domestic and international transaction monitoring, as well as real-time sanctions screening for its international payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005020/en/ Travelex Exchange Service (Photo: Business Wire) Travelex Bank is one of the world’s leading specialist providers of foreign exchange, offering a range of international money transfer products including import/export, remittances and mass payments. SONAR will empower Travelex Bank to detect attempts to launder money or circumvent financial sanctions through its system, bringing trust and confidence to all parties in the global payments ecosystem. Additionally, SONAR will allow the company to roll out n

BigCommerce utvider det globale avtrykket til Danmark, Norge, Sverige og Østerrike for å gi selgere mulighet til å skalere og få nettbutikkene sine til å vokse6.7.2022 14:00:00 CEST | Pressemelding

BigCommerce (Nasdaq: BIGC), en ledende åpen SaaS netthandelsplattform for raskt voksende og etablerte B2C- og B2B-varemerker, kunngjorde i dag at de har utvidet deres europeiske tilstedeværelse til Østerrike, Danmark, Norge og Sverige. Med sin DACH og nordiske ekspansjon og fullt lokaliserte teknologi- og byråpartner-økosystem, vil BigCommerce gjøre det mulig for selgere i alle størrelser og kompleksiteter å bygge og skalere nettbedriftene sine for å gi sømløse handleopplevelser til lokale og internasjonale kunder og øke inntektene. "BigCommerces nye tilstedeværelse i DACH og nordiske markeder gir en lokalisert, kraftig og skalerbar åpen SaaS netthandelsplattform til selgere i disse regionene som ikke tidligere har blitt tilbudt disse kjerneprinsippene i én løsning," sa Jim Herbert, senior visepresident og daglig leder EMEA hos BigCommerce. «Med vår velprøvde netthandelsplattform i enterprise-grad, vil selgere av alle typer ha de gode verktøyene og innovative funksjonalitetene – fra he

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland6.7.2022 13:45:00 CEST | Press release

KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/ KBI Biopharma and Selexis ribbon cutting at their new state-of-the-art facility in Geneva, Switzerland, Tuesday, July 5, 2022 (from left to right: Mark Lutgen, KBI Biopharma, VP of Global Engineering; Mario Rodriguez, Mayor, Plan-les-Ouates; Fabienne Fischer, State Councilor and Head of the Department of the Economy and Employment; Ma

ADVA Optical Networking SE: Approval of public exchange offer of Acorn HoldCo, Inc. by German Federal Ministry of Economics and Climate Protection6.7.2022 12:45:00 CEST | Press release

Today, the German Federal Ministry for Economics and Climate Protection (“BMWK”) has granted the foreign direct investment approval that was required for closing the public exchange offer made by ADTRAN Inc.’s subsidiary, Acorn HoldCo, Inc. (“Acorn HoldCo”). With the foreign direct investment approval by the BMWK, all offer conditions for Acorn HoldCo’s public exchange offer published on 12 November 2021 are fulfilled. The settlement of the exchange offer is expected by 15 July 2022, but at the latest on 18 July 2022. Acorn HoldCo’s shares will be admitted to trading on NASDAQ and the Frankfurt Stock Exchange. Disclaimer To the extent any announcements in this document contain forward-looking statements, such statements do not represent facts and are characterized by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of ADVA and the persons acting j

GlobalLogic Achieves Green Sustainability Ranking via the NQC SupplierAssurance Platform6.7.2022 12:00:00 CEST | Press release

GlobalLogic Inc., a Hitachi Group company and a leader in Digital Engineering, today announced it has achieved a Green rating via the NQC SupplierAssurance platform—a cloud-based solution used by suppliers to determine their sustainability performance level. Based on the Self-Assessment Questionnaire (SAQ 4.0) and validated by the NQC Supplier Assurance Team for accuracy, the results show GlobalLogic earning a score of 72% in its market category of Engineering and Research Technology Based Services. That score is significantly higher than the category average of 47% across more than 1200 locations. The automotive industry in particular has increased its focus on green initiatives. Stringent regulations and standards requiring substantial improvements to automotive manufacturing practices and direct environmental impact have been implemented in various regions. Examples range from the European Commission’s EU 2019/631 regulation targeting vehicle CO2 emissions to numerous ISO standards